| Filed On | Filing |
|---|---|
| 16 Nov 2026 |
8-K: Results of Operations and Financial Condition
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: |
| 13 Nov 2026 | 8-K: Other Events |
| 09 Nov 2026 |
8-K: Other Events
REDWOOD CITY, Calif., November 9, 2026 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat... |
| 04 Nov 2026 |
8-K: Material Modification to Rights of Security Holders; Amendments to Articles/Bylaws; Change in Fiscal Year +1 more
REDWOOD CITY, Calif., November 4, 2026 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat... |
| 15 Oct 2026 |
8-K: Other Events
Jasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy |
| 07 Oct 2026 |
8-K: Other Events
REDWOOD CITY, Calif., October 7, 2026 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper” or the “Company”), a clinical stage biotechnology company focused on the design and development of innovative therapies to treat ... |
| 05 Oct 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On September 30, 2026, Jasper Therapeutics, Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”). At the Special Meeting, a total of 21,747,865 shares of the Company’s voting common stock, $0.0001 par value... |
| 28 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On September 23, 2026, Herb Cross submitted his resignation, effective as of October 9, 2026, as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer and Corporate Secretary of Jasper Therapeutics, Inc. (the... |
| 26 Aug 2026 |
8-K: Entry into a Material Definitive Agreement
On August 21, 2026, Jasper Therapeutics, Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based on the stockholders’ equity reported in the Company’s Quarterly Repo... |
| 14 Aug 2026 |
8-K: Results of Operations and Financial Condition
Acquisition of Kira Pharmaceuticals closed in July creating a combined company with a robust portfolio of clinical stage assets focused on immunologically-driven disorders |
| 03 Aug 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On July 31, 2026, Jasper Therapeutics, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, a total of 21,121,396 shares of the Company’s voting common stock, or approximately 7... |
| 31 Jul 2026 |
8-K: Other Events
As previously disclosed by Jasper Therapeutics, Inc., a Delaware corporation (the “Company”), on a Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission (the “SEC”) on July 16, 2026 (the “Prior Form ... |
| 17 Jul 2026 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +4 more
THIS AGREEMENT AND PLAN OF MERGER is made and entered into as of July 16, 2026, by and among Jasper Therapeutics, Inc., a Delaware corporation (“Parent”), Kira Holdco Inc., a Delaware corporation and wholly owned Subsidiary of Parent (“M... |
| 16 Jul 2026 |
8-K: Regulation FD Disclosure
Combined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders |
| 09 Jun 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
On June 3, 2026, Jasper Therapeutics, Inc. (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty consecutive business days, the bid price for the Company’s... |
| 01 Jun 2026 |
8-K: Regulation FD Disclosure
REDWOOD CITY, Calif., June 1, 2026 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to ad... |
| 21 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On May 15, 2026 (the “Notice Date”), Christian Nolet informed the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) that he is resigning from the Board and the committees of the Board on which he serves, effec... |
| 14 May 2026 |
8-K: Results of Operations and Financial Condition
REDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to ad... |
| 30 Mar 2026 |
8-K: Results of Operations and Financial Condition
REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) – Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to ... |
| 08 Jan 2026 |
8-K: Other Events
Jasper Therapeutics BEACON & OLE Data Update January 8, 2026 Exhibit 99.2 |
Loading...